STXBP1

From WikiMD's WELLNESSPEDIA

STXBP1 (Syntaxin Binding Protein 1) is a protein that in humans is encoded by the STXBP1 gene. This protein is involved in the regulation of neurotransmitter release, a critical step in the neuronal communication process. Mutations in the STXBP1 gene have been associated with several neurological disorders, including Ohtahara syndrome, Dravet syndrome, and epileptic encephalopathy.

Function[edit]

STXBP1 is a crucial component of the neuronal synaptic vesicle machinery. It binds to and regulates the SNARE complex, a protein complex that mediates the fusion of synaptic vesicles with the neuronal membrane. This fusion process is essential for the release of neurotransmitters into the synaptic cleft, which allows for communication between neurons.

Clinical significance[edit]

Mutations in the STXBP1 gene can lead to a variety of neurological disorders. These mutations often result in a loss of function of the STXBP1 protein, disrupting the regulation of neurotransmitter release and leading to abnormal neuronal communication.

Ohtahara syndrome[edit]

Ohtahara syndrome is a severe form of epilepsy that begins in infancy. It is characterized by frequent seizures and severe developmental delay. Mutations in the STXBP1 gene are one of the genetic causes of Ohtahara syndrome.

Dravet syndrome[edit]

Dravet syndrome is another form of severe epilepsy that begins in infancy. It is characterized by frequent, prolonged seizures that are often triggered by high body temperature (fever), and developmental delay. Some cases of Dravet syndrome have been linked to mutations in the STXBP1 gene.

Epileptic encephalopathy[edit]

Epileptic encephalopathy is a broad term for a group of epilepsy syndromes that are characterized by severe cognitive and behavioral impairments. Mutations in the STXBP1 gene have been found in some individuals with epileptic encephalopathy.

See also[edit]

References[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.